Skip to main content

From the Helm: Clarity Pharmaceuticals Executive Chairman, Alan Taylor

Bell Direct
May 24, 2024

Embark on a journey of discovery with Dr. Alan as he unveils the cutting-edge breakthroughs of Clarity Pharma, a pioneering force in the relentless fight against cancer through next-generation radiopharmaceuticals. In this instalment of our From the helm series, Bell Direct’s Grady Wulff speaks to Clarity Pharmaceuticals (ASX:CU6) Executive Chairman, Dr Alan Taylor.

Clarity Pharmaceuticals specialises in the development of Targeted Copper Theragnostic for the imaging and treatment of selected cancers. Clarity Pharma has an extensive program of clinical development for imaging and cancer therapy with a series of important data readouts over the next few years.

In this video Dr. Alan discusses:

  • (1:27) an overview of the company, including their 7 clinical trials
  • (3:35) the promising results from their SECuRE trial
  • (11:55) why the radiopharmaceutical market is booming
  • (14:47) why Clarity Pharma could be an investment opportunity.

Morning Bell 2 May

Sophia Mavridis
May 2, 2022

Weekly Wrap 29 April

Sophia Mavridis
April 29, 2022

Morning Bell 28 April

Paulina Peters
April 28, 2022

Morning Bell 27 April

Sophia Mavridis
April 27, 2022

Morning Bell 26 April

Paulina Peters
April 26, 2022

Weekly Wrap 22 April

Sophia Mavridis
April 22, 2022

Morning Bell 21 April

Paulina Peters
April 21, 2022

Morning Bell 20 April

Sophia Mavridis
April 20, 2022

Morning Bell 19 April

Paulina Peters
April 19, 2022

Morning Bell 14 April

Paulina Peters
April 14, 2022

Morning Bell 13 April

Sophia Mavridis
April 13, 2022

Morning Bell 12 April

Paulina Peters
April 12, 2022